Opinion

Video

Use of Molecular Biomarkers Tests

Author(s):

Benjamin H. Lowentritt, MD, FACS,Brian Richardson, MD

The panel examines the significance of biomarkers in assessing therapy outcomes for prostate cancer patients, while also exploring the concept of absolute benefit in metastasis risk when adding androgen deprivation therapy (ADT) to radiation therapy for newly diagnosed cases.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Video content above is prompted by the following question:

      • What role do biomarkers play in quantifying the benefits and risks of therapy for prostate cancer patients? (Angelo A. Baccala, MD)
        • Briefly discuss the use of molecular biomarkers tests, such as Prolaris, in predicting the absolute benefit in risk of metastasis of ADT added to radiation therapy in newly diagnosed prostate cancer patients.
      Related Videos
      Dr Louise Kostos answers a question during a Zoom video interview
      Dr Louise Kostos on the rapidly evolving prostate cancer treatment landscape
      Dr Louise Kostos answers a question during a Zoom video interview
      An expert’s view on combination ARPI/ADT and long-term toxicity in prostate cancer
      Rana McKay, MD, on the role of radium-223 in the modern era
      Rana McKay, MD, on the role of radium-223 in the modern era
      Jason Hafron, MD, predicts coming advancements in bladder cancer
      Jason Hafron, MD, predicts coming advancements in bladder cancer
      Dr Louise Kostos answers a question during a Zoom video interview
      Dr Louise Kostos discusses PSA kinetics in mHSPC
      Alicia Morgans, MD, MPH, answers a question during a Zoom video interview
      The importance of PSADT in high-risk, biochemically recurrent prostate cancer
      Neeraj Agarwal, MD, outlines data on enzalutamide plus talazoparib in mCRPC
      Neeraj Agarwal, MD, outlines data on enzalutamide plus talazoparib in mCRPC
      Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
      Expert discusses triplet regimens in metastatic hormone-sensitive prostate cancer
      Alicia Morgans, MD, MPH, answers a question during a Zoom video interview
      Alicia Morgans, MD, MPH, on PSADT awareness and prostate cancer treatment initiation
      Dr Louise Kostos answers a question during a Zoom video interview
      Dr Louise Kostos discusses combination therapies in mHSPC
      Related Content
      FDA updates in urology: March 2025
      April 1st 2025

      FDA updates in urology: March 2025

      Hannah Clarke
      A recap of the FDA submissions and regulatory decisions in urology from March 2025.
      Dr. Murphy on increasing diversity in cancer clinical trials
      February 29th 2024

      Dr. Murphy on increasing diversity in cancer clinical trials

      Urology Times staff
      In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
      NeuroSAFE procedure for RARP leads to improved erectile function
      March 27th 2025

      NeuroSAFE procedure for RARP leads to improved erectile function

      Hannah Clarke
      “Our results show that by using NeuroSAFE, nearly twice as many men don’t have to face potentially life-changing loss of erectile function after prostate surgery,” says Professor Greg L. Shaw.
      Dr. Schwen on focal therapies for prostate cancer
      January 11th 2024

      Dr. Schwen on focal therapies for prostate cancer

      Cleveland Clinic
      Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
      Avoidance of prostate cancer screening linked to increased risk of PCSM
      March 21st 2025

      Avoidance of prostate cancer screening linked to increased risk of PCSM

      Hannah Clarke
      “Our study identifies that men who were invited for screening, but do not attend screening appointments are at significantly higher risk of dying from prostate cancer compared to men who were not offered screening or accepted an invitation for screening,” says Renée Leenen MD.
      Trial launches of CBP/p300 inhibitor in mCRPC
      March 20th 2025

      Trial launches of CBP/p300 inhibitor in mCRPC

      Hannah Clarke
      Pocenbrodib is an oral, small molecule designed to inhibit the proteins CREBBP/EP300, which activate genes that promote cancer cell growth and proliferation.
      © 2025 MJH Life Sciences

      All rights reserved.